Desmopressin Acetate

Desmopressin Acetate (1-deamino-8-D-arginine vasopressin) is a synthetic analog of arginine vasopressin (antidiuretic hormone, or ADH). Desmopressin Acetate is used to prevent or control symptoms of central diabetes insipidus. Desmopressin Acetate is also used to control polydipsia and polyuria that occur following pituitary surgery or head trauma.

Desmopressin Acetate’s innovator is Sanofi Aventis-Global and is known world-wide by the brand names: Ddavp, Ddavp Rhinal Tube, Minirin and Stimate.

Desmopressin Acetate acts similarly to native vasopressin. Also known as antidiuretic hormone (ADH), vasopressin is secreted by the hypothalamus in response to hyperosmolarity, volume depletion, stress (emotional or physiological), certain drugs, and painful stimuli. Vasopressin also causes constriction of vascular smooth muscle and contraction of smooth muscle in the GI tract and uterus. Response to vasopressin is mediated through two receptors: the V1 receptor, which mediates smooth muscle contraction in the peripheral vasculature, and the V2 receptor, which regulates water resorption in the collecting ducts. Desmopressin Acetate is a strong V2 agonist and has no effect on V1 receptors. Desmopressin Acetate has slight structural variations that reduce its affinity for V1 receptors and lessen its vasopressin activity and contractile action on visceral smooth muscle. When administered to patients with central diabetes insipidus,

Desmopressin Acetate works by causing a reduction in urine output with an accompanying increase in urine osmolality and a decrease in clinical symptoms of urinary frequency and nocturia are noted following Desmopressin Acetate treatment.

Desmopressin Acetate increases plasma factor VIII (FVIII) and von Willebrand factor (vWF) to a greater extent than equivalent weights of vasopressin. Desmopressin Acetate has also been used in congenital or acquired bleeding disorders, including drug-induced platelet dysfunction (e.g., aspirin, dextran, ticlopidine, and heparin). Desmopressin Acetate may promote an increased exposure of platelet vWF to GPIIb/IIIa on the platelet surface upon activation of the platelet. Levels of FVIII are also increased, which increases hemostasis by accelerating fibrin formation.

Desmopressin Acetate appears in the following formation and dosage:
Tablets 0.1, 0.2mg
Nasal spray: 0.01 mg/Actuation
Injection: 4mcg/ml.
Nasal Solution: 0.01 %

General data on Desmopressin Acetate Active Pharmaceutical Ingredient

CAS Registry: 62288-83-9 (anhydrous desmopressin acetate);62357-86-2 (desmopressin acetate trihydrate)
ATC: H01BA02
Molecular Formula: C46H64N14O12S2,C2H4O2,3H2O
Molecular Weight: 1183.3
Pharmacopoeias: In US.

Ph. Eur. 5.5: Desmopressin Acetate is a white fluffy powder. Desmopressin Acetate is soluble in water, in alcohol, and in glacial acetic acid.

TAPI's Desmopressin Acetate Active Pharmaceutical Ingredient

TAPI's Desmopressin Acetate Active Pharmaceutical Ingredient is produced in Assia Industries Limited –Teva Tech site in Beer Sheva, Israel.

Over the last 15 years TAPI has developed the expertise in developing and commercialization of peptide Active pharmaceutical ingredients, such as Desmopressin Acetate. With numerous worldwide approvals, we are continuously driven by the goal of helping our customers achieve success-and ultimately approval for their peptide APIs. We offer grams to hundred kilograms production capabilities, comprehensive technology platform including solid phase, solution phase, and hybrid approach, combined with a well established scientific experience, enabling the implementation of efficient process aimed for high quality product. We offer Custom Synthesis and Manufacturing services on peptide Active pharmaceutical ingredients.

TAPI provide full service on Desmopressin Acetate and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Desmopressin Acetate.

Other peptides available on TAPI's portfolio are: Bivalirudin, Eptifibatide, Exenatide, Tariparatide Acetate, Leuprolide/ Leuprorelin Acetate and Octreotide Acetate.Contact us today for sample availability and any other information on these products.

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products  that  Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).

*TAPI stands for Teva's Active Pharmaceutical Ingredients